QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
TSE:GUD

Knight Therapeutics (GUD) Stock Forecast, Price & News

C$4.91
+0.03 (+0.61%)
(As of 06/6/2023 ET)
Compare
Today's Range
C$4.82
C$4.91
50-Day Range
C$4.35
C$4.96
52-Week Range
C$4.28
C$6.20
Volume
124,835 shs
Average Volume
124,759 shs
Market Capitalization
C$534.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$5.97

Knight Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
21.5% Upside
C$5.97 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Knight Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars


GUD stock logo

About Knight Therapeutics (TSE:GUD) Stock

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GUD Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Closing Bell: Knight Therapeutics Inc up on Monday (GUD)
Knight Therapeutics (TSE:GUD) Price Target Cut to C$6.50
Knight Therapeutics (TSE:GUD) Hits New 52-Week Low at $4.92
Knight Therapeutics Inc
See More Headlines

GUD Price History

GUD Company Calendar

Last Earnings
3/23/2023
Today
6/06/2023
Next Earnings (Estimated)
8/10/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$5.97
High Stock Price Forecast
C$6.50
Low Stock Price Forecast
C$5.40
Forecasted Upside/Downside
+23.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

P/E Growth
-1013.5
Net Income
C$-15,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$312.35 million
Cash Flow
C$1.26 per share
Book Value
C$7.44 per share

Miscellaneous

Free Float
N/A
Market Cap
C$526.79 million
Optionable
Not Optionable
Beta
0.52

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 53)
    BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
    Comp: $455.25k
  • Ms. Samira Sakhia BCom (Age 54)
    CA, CPA, MBA, Pres, CEO & Director
    Comp: $691.66k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Bus. Officer
  • Mr. Jeff Martens
    Global VP Commercial
  • Mr. Leopoldo Bosano
    Vice-Pres of Manufacturing & Operations
  • Ms. Daniela Marino
    Global VP of Legal & Compliance
  • Ms. Susan Caroline Emblem
    Global VP of HR
  • Ms. Jody Engel
    Sr. Director of Bus. Devel.













GUD Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GUD shares.
View GUD analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2023?

2 brokerages have issued twelve-month target prices for Knight Therapeutics' stock. Their GUD share price forecasts range from C$5.40 to C$6.50. On average, they predict the company's stock price to reach C$5.97 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for GUD
or view top-rated stocks among Wall Street analysts.

How have GUD shares performed in 2023?

Knight Therapeutics' stock was trading at C$5.18 on January 1st, 2023. Since then, GUD shares have decreased by 6.6% and is now trading at C$4.84.
View the best growth stocks for 2023 here
.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GUD earnings forecast
.

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc. (TSE:GUD) released its earnings results on Thursday, March, 23rd. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $81.66 million for the quarter, compared to analyst estimates of $62 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 1.82% and a negative net margin of 4.81%.

What other stocks do shareholders of Knight Therapeutics own?
What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$4.84.

How much money does Knight Therapeutics make?

Knight Therapeutics (TSE:GUD) has a market capitalization of C$526.79 million and generates C$312.35 million in revenue each year. The company earns C$-15,020,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis.

How many employees does Knight Therapeutics have?

The company employs 660 workers across the globe.

How can I contact Knight Therapeutics?

The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483.

This page (TSE:GUD) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -